Literature DB >> 17456730

Acute adrenal insufficiency after a single dose of etomidate.

Jonathan B Lundy1, Matthew L Slane, James D Frizzi.   

Abstract

Acute adrenocortical insufficiency is a critical care emergency characterized by hemodynamic instability, lethargy, and cardiovascular collapse. Acute adrenal insufficiency has many etiologies, from rapid withdrawal of exogenous glucocorticoids to adrenocortical destruction to poor adrenal reserve after administration of steroid synthesis inhibitors. Etomidate, a parenteral hypnotic agent, is a steroid synthesis inhibitor. Although the use of continuous etomidate infusion in the intensive care unit fell from favor secondary to reports of adrenal crisis, single-dose etomidate for induction of anesthesia is common for the hemodynamically unstable patient or in patients who may not tolerate wide variance in heart rate or blood pressure. A case is presented of acute adrenocortical insufficiency and crisis after a standard induction dose of etomidate. Acute adrenal insufficiency should be suspected in intensive care unit patients who have undergone general anesthesia with etomidate induction and present with hypotension refractory to standard vasopressor administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456730     DOI: 10.1177/0885066606298140

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  10 in total

1.  Opioid and benzodiazepine contributions to etomidate-associated adrenal insufficiency.

Authors:  Harry Daniell
Journal:  Intensive Care Med       Date:  2008-09-16       Impact factor: 17.440

2.  Effects of different etomidate doses on intraoperative somatosensory-evoked potential monitoring.

Authors:  X-L Meng; L-W Wang; W Zhao; X-Y Guo
Journal:  Ir J Med Sci       Date:  2014-07-25       Impact factor: 1.568

Review 3.  Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

Authors:  Jens Heyn; Carolin Geiger; Christian L Hinske; Josef Briegel; Florian Weis
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

4.  Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Authors:  Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

5.  Vascular aging and hemodynamic stability in the intraoperative period.

Authors:  Ferrante S Gragasin; Stephane L Bourque; Sandra T Davidge
Journal:  Front Physiol       Date:  2012-04-02       Impact factor: 4.566

Review 6.  Guidelines for Perioperative Management of the Diabetic Patient.

Authors:  Sivakumar Sudhakaran; Salim R Surani
Journal:  Surg Res Pract       Date:  2015-05-19

7.  Comparison of procedural sedation for the reduction of dislocated total hip arthroplasty.

Authors:  Jonathan E Dela Cruz; Donald N Sullivan; Eric Varboncouer; Joseph C Milbrandt; Myto Duong; Scott Burdette; Daniel O'Keefe; Steven L Scaife; Khaled J Saleh
Journal:  West J Emerg Med       Date:  2014-02

8.  Comparison of cardiovascular response to laryngoscopy and tracheal intubation after induction of anesthesia by Propofol and Etomidate.

Authors:  Mehrdad Masoudifar; Elham Beheshtian
Journal:  J Res Med Sci       Date:  2013-10       Impact factor: 1.852

9.  Effect of Etomidate Versus Combination of Propofol-Ketamine and Thiopental-Ketamine on Hemodynamic Response to Laryngoscopy and Intubation: A Randomized Double Blind Clinical Trial.

Authors:  Afshin Gholipour Baradari; Abolfazl Firouzian; Alieh Zamani Kiasari; Mohsen Aarabi; Seyed Abdollah Emadi; Ali Davanlou; Nima Motamed; Ensieh Yousefi Abdolmaleki
Journal:  Anesth Pain Med       Date:  2016-01-10

Review 10.  Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient's Perspective.

Authors:  Kim M J A Claessen; Cornelie D Andela; Nienke R Biermasz; Alberto M Pereira
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-20       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.